Everest Medicines

News

23 2023/03

Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases
16 2023/03

Everest Medicines Announces Approval of Xerava in China for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
15 2023/03

Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
14 2023/03

Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy
13 2023/03

Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company
28 2023/02

Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility
10 2023/02

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy
18 2023/01

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
03 2023/01

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
30 2022/12

Everest Medicines to Hold New Corporate Strategy Conference Calls
30 2022/12

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
28 2022/12

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号